menu

Dr. Charles Turck and Dr. Maryam Lustberg Discuss What's Ahead in HER2-low breast cancer

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Addressing Unmet Needs in HER2-Low Breast Cancer Care  

ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Media formats available:
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    Amid the evolving treatment landscape for HER2-low breast cancer, many therapeutic challenges and limitations remain, resulting in unmet needs for our patients. Fortunately, developments in the therapeutic landscape can help address those unmet needs, and joining Dr. Charles Turck to share what’s on the horizon is Dr. Maryam Lustberg.

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    Amid the evolving treatment landscape for HER2-low breast cancer, many therapeutic challenges and limitations remain, resulting in unmet needs for our patients. Fortunately, developments in the therapeutic landscape can help address those unmet needs, and joining Dr. Charles Turck to share what’s on the horizon is Dr. Maryam Lustberg.

Facebook Comments

Schedule16 May 2022
Webpack App